Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock: Insider Jennifer Jarrett Acquires 12,500 Shares

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett acquired 12,500 shares of the company’s stock in a transaction on Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Damora Therapeutics, Inc. Common Stock Price Performance

Damora Therapeutics, Inc. Common Stock stock opened at $20.66 on Wednesday. The stock has a market capitalization of $1.28 billion, a PE ratio of -6.13 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a 12 month low of $3.50 and a 12 month high of $38.33. The business has a 50 day simple moving average of $27.94 and a 200-day simple moving average of $26.22.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.06. On average, equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $42,146,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth $7,398,000. Squarepoint Ops LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $303,000. Finally, Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $260,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DMRA. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Finally, Guggenheim lifted their price objective on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has a consensus rating of “Buy” and an average target price of $46.50.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.